Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nelso Obus, Wynnefield Capital Further Increase Holding Of Nature’s Sunshine Prod. (NATR)

Nelson Obus, the manager of Wynnefield Capital, is still optimistic about the prospects of Nature’s Sunshine Prod. (NASDAQ:NATR) and has increased his fund’s holding of the stock. According to a recent Form 4 filing with the Securities and Exchange Commission, Wynnefield Capital has added 20,851 Nature’s Sunshine Prod. (NASDAQ:NATR) shares to its portfolio in 9 transactions at prices varying between $15.96 and $16.04. Following this move, Obus and Wynnefield Capital have amassed 1.69 million shares.

Nelson Obus

Nature’s Sunshine Prod. (NASDAQ:NATR) has also attracted the attention of Phil Frohlich. His fund, Prescott Group Capital Management, holds 1.86 million shares, as reported in its latest 13F filing. Willem Mesdag is also a fan of this stock and has built a 2.43 million shares position for his fund, Red Mountain Capital. This position also accounts for 10.65% of Red Mountain’s equity portfolio. A somewhat smaller stake is held by Jim Simons and his fund, Renaissance Technologies: approximately 123,000 shares.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!